MIBG Therapy for High Risk Neuroblastoma at UCSF

UCSF Oncologists Lead the Way with MIBG Therapy  

The UCSF Pediatric Oncology Team has led the way with MIBG treatments for over 25 years. 

Dr. Katherine Matthay first tested MIBG in a patient in 1986 and has continually pushed for clinical research to improve the treatment for kids with the most advanced stages of neuroblastoma. 

Our center is one of the few centers in the nation which offers this treatment, offering guidance to other hospitals interested in providing MIBG therapy. The entire team is specially trained to support and meet the needs of young and older children and families undergoing this treatment.

We conduct several MIBG therapy studies for the treatment of neuroblastoma and pheochromocytoma.

MIBG therapy is only offered by entering a study or clinical trial because it is not yet FDA approved. 

The study a child enters will depend upon a number of factors, including open studies and their prior treatment.

The length of stay will vary depending on the study the child participates in. 

We now offer medications for young children to help them stay calm during their hospitalization for their safety and the success of MIBG therapy.